Palifermin

N/A

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NamePalifermin
Drug Alias NameKeratinocyte growth factor帕利夫明Recombinant human keratinocyte growth factorpaliferminumpalifermine +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionFibroblast growth factor receptors agonists
TargetsFibroblast growth factor receptors
Therapy Area/IndicationsRadiation InjuriesDrug-Related Side Effects and Adverse ReactionsMyelodysplastic Syndromes +[16] 
Global Approved IndicationsStomatitisMucositis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2004/12/15
Country/TerritoryUnited StatesGermanyEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSobiAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesSwedish Orphan Biovitrum AgBiovitrum Ab
Inactive CompaniesSwedish Orphan Biovitrum (Sobi)Swedish Orphan Biovitrum Ab (Publ)National Cancer Institute +[6] 
Active IndicationsStomatitis
Inactive IndicationsRadiation InjuriesDrug-Related Side Effects and Adverse ReactionsMyelodysplastic Syndromes +[15] 

Other Information

ATC CodeV03AF08
Related LinksWikipediaDrugBankKEGG